• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Point of care with serial N-terminal pro-B-type natriuretic peptide (NT-proBNP) for heart failure in patients with acute decompensation. An invited commentary.急性失代偿患者心力衰竭的床旁连续检测N末端B型利钠肽原(NT-proBNP)。特邀评论
Contemp Clin Trials Commun. 2022 Jan 25;26:100889. doi: 10.1016/j.conctc.2022.100889. eCollection 2022 Apr.
2
Point-of-care testing of (N-terminal pro) B-type natriuretic peptide for heart disease patients in home care and ambulatory care settings.在家居护理和门诊护理环境中对心脏病患者进行(N 端前体)B 型利钠肽的即时检测。
Pract Lab Med. 2020 Oct 17;22:e00183. doi: 10.1016/j.plabm.2020.e00183. eCollection 2020 Nov.
3
Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.强化、N 末端 pro-B 型利钠肽指导与症状指导治疗老年心力衰竭患者的长期结果:TIME-CHF 的 5 年随访。
Circ Heart Fail. 2014 Jan;7(1):131-9. doi: 10.1161/CIRCHEARTFAILURE.113.000527. Epub 2013 Dec 18.
4
Effects of serial NT-proBNP measurements in patients with acute decompensated heart failure: Results of the POC-HF pilot trial.急性失代偿性心力衰竭患者连续检测N末端B型利钠肽原(NT-proBNP)的效果:POC-HF试点试验结果
Glob Cardiol Sci Pract. 2024 Aug 1;2024(4):e202431. doi: 10.21542/gcsp.2024.31.
5
Point-of-care NT-proBNP monitoring for heart failure: observational feasibility study in primary care.用于心力衰竭的即时检测N末端B型利钠肽原监测:基层医疗中的观察性可行性研究
BJGP Open. 2022 Sep 28;6(3). doi: 10.3399/BJGPO.2022.0005. Print 2022 Sep.
6
Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.Pro-B 型利钠肽门诊个体化慢性心力衰竭治疗(PROTECT)研究的设计和方法。
Am Heart J. 2010 Apr;159(4):532-538.e1. doi: 10.1016/j.ahj.2010.01.005.
7
NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?).NT-proBNP(氨基末端脑利钠肽前体)指导急性失代偿性心力衰竭治疗的研究:PRIMA II 随机对照试验(急性失代偿性心力衰竭住院期间 NT-proBNP 指导治疗能否降低死亡率和再入院率?)
Circulation. 2018 Apr 17;137(16):1671-1683. doi: 10.1161/CIRCULATIONAHA.117.029882. Epub 2017 Dec 14.
8
Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure: A Health Technology Assessment.B 型利钠肽(BNP)和氨基末端 B 型利钠肽前体(NT-proBNP)在疑似心力衰竭成人中的诊断检测作用:卫生技术评估。
Ont Health Technol Assess Ser. 2021 May 6;21(2):1-125. eCollection 2021.
9
Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.比较中段心房利钠肽原与N末端B型利钠肽原在预测慢性心力衰竭患者生存率中的作用
J Am Coll Cardiol. 2007 Nov 13;50(20):1973-80. doi: 10.1016/j.jacc.2007.08.012. Epub 2007 Oct 29.
10
Point-of-care N-terminal pro B-type natriuretic peptide assay to screen apparently healthy cats for cardiac disease in general practice.在一般实践中,使用即时检测 N 末端 pro B 型利钠肽检测对貌似健康的猫进行心脏疾病筛查。
J Vet Intern Med. 2021 Jul;35(4):1663-1672. doi: 10.1111/jvim.16156. Epub 2021 May 16.

引用本文的文献

1
Non-Invasive Assessment of Congestion by Cardiovascular and Pulmonary Ultrasound and Biomarkers in Heart Failure.心力衰竭中通过心血管和肺部超声及生物标志物对充血进行无创评估
Diagnostics (Basel). 2022 Apr 12;12(4):962. doi: 10.3390/diagnostics12040962.

本文引用的文献

1
Point of care with serial NT-proBNP measurement in patients with acute decompensated heart failure as a therapy-monitoring during hospitalization (POC-HF): Study protocol of a prospective, unblinded, randomized, controlled pilot trial.急性失代偿性心力衰竭患者住院期间采用连续NT-proBNP测量进行即时护理作为治疗监测(POC-HF):一项前瞻性、非盲、随机、对照试验的研究方案
Contemp Clin Trials Commun. 2021 Aug 19;23:100825. doi: 10.1016/j.conctc.2021.100825. eCollection 2021 Sep.
2
MMP inhibitors attenuate doxorubicin cardiotoxicity by preventing intracellular and extracellular matrix remodelling.基质金属蛋白酶抑制剂通过预防细胞内和细胞外基质重塑来减轻阿霉素的心脏毒性。
Cardiovasc Res. 2021 Jan 1;117(1):188-200. doi: 10.1093/cvr/cvaa017.
3
Promptly reporting of critical laboratory values in pediatrics: A work in progress.及时报告儿科危急检验值:一项正在进行的工作。
World J Clin Pediatr. 2018 Nov 12;7(5):105-110. doi: 10.5409/wjcp.v7.i5.105.
4
Accuracy, user-friendliness and usefulness of the Cobas h232 point-of-care test for NT-proBNP in primary care.Cobas h232 即时检验 NT-proBNP 在初级保健中的准确性、用户友好性和实用性。
J Clin Pathol. 2018 Jun;71(6):539-545. doi: 10.1136/jclinpath-2017-204746. Epub 2017 Dec 20.
5
NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?).NT-proBNP(氨基末端脑利钠肽前体)指导急性失代偿性心力衰竭治疗的研究:PRIMA II 随机对照试验(急性失代偿性心力衰竭住院期间 NT-proBNP 指导治疗能否降低死亡率和再入院率?)
Circulation. 2018 Apr 17;137(16):1671-1683. doi: 10.1161/CIRCULATIONAHA.117.029882. Epub 2017 Dec 14.
6
Cardiovascular dysfunction in sepsis at the dawn of emerging mediators.脓毒症中新兴介质出现时的心血管功能障碍。
Biomed Pharmacother. 2017 Nov;95:153-160. doi: 10.1016/j.biopha.2017.08.066. Epub 2017 Sep 12.
7
Autophagy-Inflammasome Interplay in Heart Failure: A Systematic Review on Basics, Pathways, and Therapeutic Perspectives.心力衰竭中自噬与炎性小体的相互作用:关于基础、途径及治疗前景的系统综述
Ann Clin Lab Sci. 2017 May;47(3):243-252.
8
Predictors of Left Ventricular Functional Recovery and Their Impact on Clinical Outcomes in Patients With Newly Diagnosed Dilated Cardiomyopathy and Heart Failure.新诊断扩张型心肌病和心力衰竭患者左心室功能恢复的预测因素及其对临床结局的影响
Heart Lung Circ. 2018 Jan;27(1):41-49. doi: 10.1016/j.hlc.2017.02.013. Epub 2017 Mar 20.
9
Exome-wide association study reveals novel susceptibility genes to sporadic dilated cardiomyopathy.全外显子组关联研究揭示了散发性扩张型心肌病的新易感基因。
PLoS One. 2017 Mar 15;12(3):e0172995. doi: 10.1371/journal.pone.0172995. eCollection 2017.
10
Evaluation of NT-proBNP in children with heart failure younger than 3 years old.3岁以下心力衰竭儿童的N末端B型利钠肽原评估。
Rom J Intern Med. 2017 Jun 1;55(2):69-74. doi: 10.1515/rjim-2017-0002.

急性失代偿患者心力衰竭的床旁连续检测N末端B型利钠肽原(NT-proBNP)。特邀评论

Point of care with serial N-terminal pro-B-type natriuretic peptide (NT-proBNP) for heart failure in patients with acute decompensation. An invited commentary.

作者信息

Sergi Consolato M

机构信息

Anatomy Pathology Division, Children's Hospital of Eastern Ontario, University of Ottawa, ON, Canada.

Departments of Pediatrics and Laboratory Medicine, University of Alberta, Edmonton, AB, Canada.

出版信息

Contemp Clin Trials Commun. 2022 Jan 25;26:100889. doi: 10.1016/j.conctc.2022.100889. eCollection 2022 Apr.

DOI:10.1016/j.conctc.2022.100889
PMID:36684692
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9846449/
Abstract

Point-of-care (POC) Testing (POCT) is a medical diagnostic approach carried out outside the clinical laboratory and close to the patient. The results are used for the immediate clinical decision to improve patient care. Accreditation Canada and Diagnostic Accreditation Programs regulatory standards and the College of the American Pathologists for POCT have implemented several guidelines and certifications. POC in heart failure (POC-HF) will demonstrate that it is helpful to develop a preliminary understanding of the value of serial N-terminal -B-type   (NT-proBNP) measurements in the diagnostic and therapeutic process in patients hospitalized with acute decompensation of heart failure. In addition, POC-HF will hopefully answer questions on the workability of this approach in clinical routine and the usefulness and justification to perform larger-scale studies investigating this strategy.

摘要

即时检验(POC)是一种在临床实验室之外、靠近患者处进行的医学诊断方法。其结果用于立即做出临床决策以改善患者护理。加拿大认证机构和诊断认证计划监管标准以及美国病理学家学会针对即时检验已实施了多项指南和认证。心力衰竭即时检验(POC-HF)将证明,对于初步了解连续测定N末端B型利钠肽原(NT-proBNP)在急性失代偿性心力衰竭住院患者诊断和治疗过程中的价值是有帮助的。此外,POC-HF有望回答关于该方法在临床常规中的可行性以及开展更大规模研究以调查此策略的实用性和合理性等问题。